Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders

Trial Profile

Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs HBAI 20 (Primary) ; Hepatitis B vaccine recombinant (HBvaxPro)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 13 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 29 Apr 2016 According to a CyTuVax media release, all subjects have been vaccinated twice and the data from this trial will be published in the third quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top